Dialysis · Infection Prevention · Quality Tool

Access Infection Rate with Exact 95% CI

Report access infections the way surveillance programs do: events per 1,000 exposure-days with an exact confidence interval that stays honest at zero events. A scenario panel turns published lock-trial rates into absolute numbers for your unit, and an explainer separates absolute from relative effects.

Published: References: 4 Read time:

← All calculators & tools  ·  Access lifeline guide →

Last ReviewedHuling Na-reviewKatapusang Na-reviewKarinan Na-review:
Instructions
  1. Enter the number of events and the matching exposure days (catheter-days for catheter infections, access-days for all accesses). The definition must match the denominator.
  2. Choose the event definition. Catheter-related bloodstream infection (CRBSI), all bloodstream infection (BSI), and surveillance access-related BSI are different events and are not interchangeable.
  3. Read the rate per 1,000 days with its exact 95% confidence interval. Zero events give a rate of zero with a real, nonzero upper bound.
  4. Use the scenario panel to see what a published trial’s rates would mean in absolute numbers over your unit’s catheter-days.

All computation runs in your browser; no values are stored or transmitted.

When to Use

For facility quality review: monthly or quarterly infection rates, before-and-after comparisons, and teaching. It is a unit metric, not an individual patient’s infection risk. Do not convert patient-month surveillance rates casually into catheter-day rates; reporting systems such as the National Healthcare Safety Network (NHSN) use their own definitions.

Access Infection Rate with Exact 95% CI

Whole number.
Catheter-days or access-days, matching the event definition.
—
Rate
per 1,000 days
—
Lower 95% bound
per 1,000 days
—
Upper 95% bound
per 1,000 days
—
Events / days

⚕ Rate = events ÷ exposure days × 1,000. Exact (Garwood) Poisson interval computed by bisection on the Poisson distribution; verified against chi-square quantiles from SciPy for 0, 1, 3, 9, 32, and 100 events.

Constant-rate scenario (published trial rates)

Default rates are from LOCK IT-100: 0.46 per 1,000 catheter-days with heparin and 0.13 with taurolidine/heparin. Edit them for your own baseline. This is a planning illustration that assumes a constant rate; it is not a forecast and does not assume the trial hazard ratio applies to your unit.

—
Expected events, A
events
—
Expected events, B
events
—
Difference
events

Absolute versus relative effect (binary outcomes)

For trials reporting the proportion with an event over the same fixed horizon in each arm. Not valid for Kaplan–Meier patency estimates, rates per patient-day, odds ratios, or hazard ratios.

—
Absolute difference
percentage points
—
Relative reduction
%
—
NNT or NNH
patients
Formula & Evidence
QuantityFormula
Rate per 1,000 daysevents ÷ exposure days × 1,000
Exact 95% CI (k events)lower = μ where P(X ≥ k) = 0.025; upper = μ where P(X ≤ k) = 0.025; divide by days × 1,000
Scenario eventsrate × catheter-days ÷ 1,000
Absolute risk reduction (ARR)control risk − treatment risk; number needed to treat (NNT) = ceil(1 ÷ ARR) only when ARR > 0

LOCK IT-100: 795 adults dialyzing via catheter at 70 United States sites; CRBSI 0.13 versus 0.46 per 1,000 catheter-days; hazard ratio 0.29 (95% CI 0.14–0.62). The 71% figure is a relative hazard reduction, not an absolute one. Apixaban after thrombectomy (186 patients, open label): recurrent thrombosis 24.0% versus 40.8% at 3 months; minor bleeding 22.6% versus 7.5%. FAVOURED: fistula failure 128/270 (47.4%) with fish oil versus 125/266 (47.0%) with placebo.

Important: This tool is an educational aid for licensed clinicians and dialysis quality teams. It performs transparent arithmetic on the values you enter; it does not diagnose, predict an individual patient’s risk, or recommend a procedure or drug. All computation runs in your browser; nothing is stored or transmitted. Urgent symptoms (uncontrolled bleeding, a lost thrill, a cold or painful hand, fever with rigors, chest pain or breathlessness) need emergency assessment, not a calculation.
References 4 sources
  1. Agarwal, A. K., Roy-Chaudhury, P., Mounts, P., Hurlburt, E., Pfaffle, A., & Poggio, E. C. (2023). Taurolidine/heparin lock solution and catheter-related bloodstream infection in hemodialysis: A randomized, double-blind, active-control, phase 3 study. Clinical Journal of the American Society of Nephrology, 18(11), 1446–1455. https://doi.org/10.2215/CJN.0000000000000278
  2. Centers for Disease Control and Prevention (CDC). (2024, March 29). Best practices for bloodstream infection prevention in dialysis setting. U.S. Department of Health and Human Services. https://www.cdc.gov/dialysis-safety/hcp/clinical-safety/
  3. Ko, T.-Y., Wu, C.-C., Hsieh, M.-Y., Yang, C.-W., Cheng, C.-H., Chen, C.-K., & Kao, H.-L. (2025). A randomized controlled trial evaluated the efficacy and safety of apixaban for prevention of recurrent thrombosis after thrombectomy of hemodialysis vascular access. Kidney International, 107(2), 348–358. https://doi.org/10.1016/j.kint.2024.10.023
  4. Irish, A. B., Viecelli, A. K., Hawley, C. M., Hooi, L.-S., Pascoe, E. M., Paul-Brent, P.-A., Badve, S. V., Mori, T. A., Cass, A., Kerr, P. G., Voss, D., Ong, L.-M., & Polkinghorne, K. R. (2017). Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: A randomized clinical trial. JAMA Internal Medicine, 177(2), 184–193. https://doi.org/10.1001/jamainternmed.2016.8029
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info

Scan and save

All Calculators Related Guides